As India Businesses Transform, Top Level Changes Effected At Abbott, Roche
This article was originally published in PharmAsia News
Leadership changes said to focus on better access, strategic business direction
You may also be interested in...
Abbott Established Products Senior VP Michael Warmuth Stresses Diversified Portfolio In Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)
Michael Warmuth, senior vice president, Established Products Division, Abbott Laboratories handles emerging markets, one of the most ambitious growth areas for his company. Amongst the EMs, India stands as a sharp focus market, demonstrated last year by its acquisition of Piramal Healthcare Ltd.'s prescriptions business for $3.72 billion. Warmuth says India is on top of his priority list and though critics may question the high price that Abbott paid for the Piramal business, there is a large potential to tap the "incredibly high unmet medical need."
Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical
MUMBAI - Piramal Healthcare Chairman Ajay Piramal redefined the valuation processes for Indian life science companies last week, when he sold his domestic business of predominantly 350 branded generic products to Illinois-based Abbott for $3.72 billion - a jaw-dropping price that is nine times the level of annual sales and 31 times that of earnings
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.